NICE no for Roche's Avastin for breast cancer
This article was originally published in Scrip
Executive Summary
NICE, the National Institute for health and Clinical Excellence, said in draft guidance on 9 July that it was not inclined to recommend Roche's VEGF-targeted Avastin (bevacizumab), in combination with a taxane, as a first line treatment for metastatic breast cancer for NHS patients in England and Wales.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.